RxDoctor Payments Data

Jorge Rios-Perez, MD

Hematology & Oncology · Columbus, OHNPI 1710143847

Payments from drug & device makers

$353,279in general payments, 2019–2025

Across 213 payments — averaging $1658.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mirati Therapeutics, Inc.$192K
  • AstraZeneca$115K
  • Genentech, Inc.$41K
  • Puma Biotechnology, Inc.$4K
  • Eisai Inc.$339
  • AVEO Pharmaceuticals, Inc.$182
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$2,52894%
  • Education$1566%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$353,279 in reported general payments places this provider in the 75th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,306,820
Medicare patients
225
Services billed
51,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide43$579,589
PomalystPomalidomide14$314,539
TagrissoOsimertinib Mesylate19$313,719
ImbruvicaIbrutinib14$208,559
Lenalidomide11$174,440
EliquisApixaban27$21,460
Tamoxifen Citrate13$718
Anastrozole36$571
Prochlorperazine Maleate39$552
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$413
Dexamethasone37$382
Hydroxyurea19$351
Letrozole31$267
Acyclovir17$227
Ondansetron OdtOndansetron13$177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$115$579,58943 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$117$314,53914 claims
AstraZenecaTagrisso$114,779$313,71919 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$44$208,55914 claims
PfizerEliquis$144$21,46027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →